Which companies are developing ALK7 obesity drugs? Roche’s Rona deal joins Arrowhead and GSK programmes, but human data remain early.
ALK7 Obesity Drugs: Who Is Developing Them After Roche’s Rona Deal?
read more
Biotech
Beyond Binding: Functional Prediction in GPCR Drug Discovery
In GPCR drug discovery, as elsewhere, teams know the cost of getting early decisions wrong. A corrected JAMA analysis of 63 new drugs and biologics approved by the US Food and Drug Administration between 2009 and 2018 estimated the median capitalised R&D...
Pharmacogenomics Has Left the Lab. Now Comes the Hard Part.
In every industry, there is a lag period between breakthrough and implementation, but perhaps none so long as in healthcare, where medical advances such as pharmacogenomics (PGx) might not show up in practices for years or even decades. While there are myriad reasons...
The Future of Diagnostics Is Molecularly Precise
The landscape of modern healthcare is increasingly reliant on the speed, accuracy, and accessibility of In Vitro Diagnostics (IVD). From rapid point-of-care infectious disease tests to complex oncology biomarker profiling, IVD assays play a central role in clinical...
EGFR Exon 20 Insertion Trial Misses Its Primary Endpoint
ArriVent’s FURVENT Phase 3 missed its primary endpoint in EGFR exon 20 insertion lung cancer. LSDN examines the UK access position.
Younger TAVR Patients Raise the Bar for Long-Term Valve Performance
As transcatheter aortic valve replacement (TAVR) expands into younger patients with longer life expectancy, the definition of a successful procedure needs to grow with it. A July 2026 international position statement identified this trend as a reason for greater focus...
Biopharma VC Funding in H1 2026: Megarounds Mask an Early-Stage Squeeze
Biopharma VC funding delivered its strongest opening half in four years. Yet the headline figure hides a widening split. Mature, de-risked companies are attracting capital, while the seed-stage startups that supply the sector’s long-term pipeline are not. Data...
In Vivo CAR-T Therapy: The Next Frontier in Cell Therapy Explained
In vivo CAR-T therapy has travelled from laboratory concept to clinical reality faster than almost any modality in recent memory. Conventional cell therapy collects a patient’s T cells, engineers them in a specialist facility and returns them weeks later. The in vivo...
Cutting Through the Noise: How AI/ML Can Guide Target Selection for Vaccines
Modern vaccine research has entered an era of colossal data abundance. Researchers can now examine complete pathogen genomes and proteomes, measure hundreds of thousands of antigen-specific antibody responses, characterize immune-cell states at single-cell resolution...
Beyond Weight Loss: What Emerging GLP-1 Research Reveals
For many years, the perception of obesity and metabolic syndrome has largely been framed within the context of lifestyle and individual choices. However, an unprecedented paradigm shift is taking place as researchers gain a more profound insight into the physiological...
Asia Is No Longer Pharma’s Factory. It Is Becoming the Source
Two deals announced within days of each other this month read, on their own, like routine deal flow news. South Korea’s Alteogen signed its seventh platform licensing agreement with a global pharmaceutical company. Fujifilm and Taiho Pharmaceutical agreed to build...
Treating Antimicrobial Resistance as a Healthcare Infrastructure Priority
Modern healthcare depends on a basic assumption: when infections occur, clinicians will have medicines that can treat them. But antimicrobial resistance (AMR) is beginning to challenge that assumption at a systems level. For many years, AMR has been discussed...
Beyond Cytotoxic Payloads: The Expansion of Non-traditional Conjugates
For over two decades, the narrative surrounding targeted biologics has been dominated by antibody-drug conjugates (ADCs) armed with cytotoxic small molecules designed to destroy cancer cells. While oncology remains a primary target for biologics, the therapeutic...
The Public Paper Trail: What Commercial Teams Find Out Last
For most of a decade, I worked on the commercial side of life sciences, and the same thing kept happening. Something would change at an account. A financing would close, a trial would move into a new phase, or a facility would receive an inspection observation. I...
Women-Led Biotech Is Outperforming. Why Is Capital Lagging?
A new therapeutic can take a decade. Often hundreds of millions of dollars. Regulators checking the work at every stage along the way. So when a category of founders consistently delivers better returns on less capital, you'd expect investment patterns to reflect...
Microalgae Biomaterials: Where the Carbon Math Holds, and Where it Fails
A research team at the University of Colorado Boulder took a marine dinoflagellate called Pyrocystis lunula, mixed it into 4 wt% sodium alginate, crosslinked the gel ionically in calcium chloride, and extruded it through a Cellink BIO X bioprinter into printed grids...
How the Gut-Brain-Metabolism Axis Is Reshaping Targeted Therapy
For decades, the fields of oncology, neuroscience, and microbiology operated in distinct silos within therapeutic research and clinical practice. Modern drug discovery, however, is rapidly witnessing a paradigm shift toward systemic biology. Researchers increasingly...
Personalized Cancer Care: How the Immune System is Reshaping Oncology
Immuno-oncology is not a new frontier, and for years, therapies like checkpoint inhibitors have reshaped how we treat certain cancers. While early approaches established that the immune system could fight cancer, the field has seen both major breakthroughs and clear...